A federal bankruptcy judge has approved Purdue Pharma’s new $7.4 billion plan to settle claims linked to the company’s role in the opioid crisis. This decision could change how large-scale lawsuits and insurance claims are handled in cases like this. The settlement aims to end a legal battle that has lasted six years and is seen as one of the most complicated bankruptcies in U.S. history.
The money for the payout will mainly come from the Sackler family, who used to own Purdue Pharma, and from the company’s remaining assets. Insurance companies will play little to no role in covering the costs, as the claims involved intentional misconduct—a category usually excluded from insurance policies. The Sacklers will give between $6.5 billion and $7 billion and will give up control of Purdue. The company will then become Knoa Pharma, a nonprofit focused on tackling the opioid epidemic.
This plan won the support of over 99 percent of creditors and sets aside funds not only for government programs aimed at fighting addiction but also nearly $865 million specifically for individual victims. Part of this will help babies born with neonatal opioid withdrawal syndrome. Governments can expect to receive payments over the next 15 years, while individual victims may get their compensation starting next year. However, those payments will be small and will require proof that the claimant was prescribed Purdue’s drugs.
The case against Purdue and the Sackler family centers on accusations that they aggressively pushed OxyContin while hiding or downplaying its risks. This marketing led to widespread addiction and thousands of deaths over the past two decades. The family denies wrongdoing but has faced heavy criticism for pulling billions from the company before it filed for bankruptcy.
An earlier version of this settlement was blocked by the Supreme Court because it would have protected the Sacklers completely from future lawsuits. The new deal does not grant such immunity, meaning the family can still face legal action from those who choose to opt out. This lack of full protection is another reason insurers have stayed away from covering these costs.
Despite some voices calling for greater criminal accountability and arguing the settlement doesn’t fully compensate victims, many have supported the plan. More than 54,000 personal injury claimants voted, and only a tiny fraction opposed it. Officials believe the settlement will finally provide much-needed funds for addiction treatment and prevention across the country.
With the judge’s green light, Purdue’s bankruptcy case is winding down. The shift to Knoa Pharma could happen as soon as 2026, marking a new chapter focused on healing instead of litigation. While the opioid crisis itself continues to impact communities deeply, this settlement may serve as a model for how big lawsuits involving intentional harm are handled, showing that insurance can’t always cover these enormous losses.